Global Leading Market Research Publisher QYResearch announces the release of its latest report “Kratom Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Kratom Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Kratom Extract was estimated to be worth US318millionin2025andisprojectedtoreachUS318millionin2025andisprojectedtoreachUS 540 million by 2032, growing at a CAGR of 7.9% from 2026 to 2032. Kratom is a tropical tree native to Southeast Asia. Kratom extract is a dietary supplement that may make people feel energized or relaxed. Despite the growing consumer interest in kratom as an alternative to opioids for pain management and as a mood enhancer, users and industry participants face two persistent pain points: product quality inconsistency (wide variation in mitragynine potency standardization across brands and batches), and regulatory uncertainty (varying legal statuses across US states, EU countries, and other nations). This report addresses these challenges by providing a data-driven roadmap for selecting kratom alkaloid profile products with consistent potency, understanding fast-acting kratom formula options, and navigating the complex regulatory landscape for botanical extract supplement products.
Kratom extract is mainly classified into the following types: powder, liquid, capsules, gummies and other. Liquid product now is the most widely used type which takes up about 34% of the total revenue, and its market share will keep growing. Kratom extract can be sold through offline retail stores and online channel. Online channel was growing faster which took up about 36% of the global market size. MIT45, VivaZen, Happy Hippo, Koi CBD, Kratomade, Kats Botanicals etc. are the key suppliers in the global Kratom extract market. Top 5 took up about 52% of the global market. Consumer concerns about product safety persist, but research into this product is still in its early stages of development, so market education remains important. At the same time, this industry is greatly affected by policies, and companies in the industry need to continue to pay high attention to the policy adjustments of the national and state governments.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5514134/kratom-extract
1. Industry Context: Why Kratom Extract Is a Rapidly Evolving Botanical Category
Over the past 18 months, three converging factors have shaped the kratom extract market. First, consumer preference shift toward convenience formats: liquid shots and gummies are growing faster (10-12% CAGR) than traditional powder (3-4% CAGR). Second, product innovation: manufacturers have introduced standardized extracts (labeled mitragynine content), flavored products, and enhanced formulations (with other botanicals like turmeric, CBD). Third, e-commerce expansion: online sales (36% share) have grown 15-20% annually, enabling direct-to-consumer brands to reach users in regulated states (careful compliance).
However, the industry faces significant headwinds: regulatory bans or restrictions in multiple jurisdictions (6 US states ban kratom; several EU countries ban; Thailand and Indonesia regulate export). The latest generation of mitragynine potency standardization features third-party lab testing (ISO 17025) and QR code batch traceability, addressing quality concerns.
2. Product Type Segmentation and Market Dynamics (2025–2026 H1 Data)
Based on proprietary tracking across 60+ kratom brands and 200,000+ consumer transactions (Q1–Q2 2026), the market is segmented into five product formats:
- Liquid Extract (34% market share, 9-10% CAGR – fastest growing): Pre-packaged shots (1-4 fl oz) or dropper bottles (tinctures). High concentration (100-200mg mitragynine per shot). Fast-acting kratom formula liquids absorb in 15-30 minutes vs. 45-90 minutes for powder/capsules. Price: USD 12-25 per shot; USD 30-60 per tincture bottle. Dominant among experienced users and those seeking rapid effects. Powder-to-liquid substitution is accelerating as consumers trade up for convenience.
- Powder (28% market share, 3-4% CAGR – mature, declining): Dried, ground kratom leaves. Traditional format, lowest cost (USD 0.10-0.30 per gram). Advantages: customizable dosing, longest shelf life. Disadvantages: bitter taste, requires preparation (mixing with liquid), slower onset. Declining share as consumers prefer convenience formats.
- Capsules (22% market share, 6-7% CAGR): Powder filled into gelatin or vegetarian capsules (typically 500-750mg each). Advantages: convenient (no taste, portable), consistent dosing (pre-measured). Disadvantages: slower onset (capsule dissolution time), higher cost per serving (USD 0.40-1.00 per capsule). Popular among beginners and medical users (discrete, easy to take).
- Gummies (10% market share, 12-13% CAGR – fastest-growing small segment): Chewable, flavored gummies (5-10mg mitragynine per piece). Advantages: palatable (masked bitter taste), fun format, discrete. Disadvantages: lower potency (many pieces needed for effect), shorter shelf life (moisture sensitivity), higher cost per mg. Popular with younger consumers and as an entry product.
- Other (6% market share: tablets, tea bags, shots + other blends): Niche formats. Tea bags (traditional preparation) declining.
Key Data Point (H1 2026): Average mitragynine content varies significantly by format: liquid shots (50-250mg per serving), powder (12-18mg per gram), capsules (10-15mg per capsule), gummies (5-15mg per piece). Kratom alkaloid profile (mitragynine:7-hydroxymitragynine ratio) also varies; 7-HMG is more potent but typically present at 1-2% of mitragynine levels.
3. Deep Dive: Format Selection Drivers – User Experience and Use Case
A unique contribution of this analysis is the segmentation by user experience level and intended use case:
- Beginners / First-Time Users: Typically start with capsules or gummies (no taste, less intimidating). Low tolerance means lower doses effective (2-4g powder-equivalent). Capsules preferred for dose control. Botanical extract supplement education is critical (start low, go slow).
- Regular / Experienced Users: Shift to powder (lower cost per dose) or liquid shots (convenience, faster onset). Powder allows custom blending of strains (red/white/green vein). Liquid shots preferred for on-the-go use (work, travel, social settings). Case Study: Happy Hippo (US brand) reported that 60% of new customers start with capsules; after 3-6 months, 40% switch to powder (cost savings) and 25% add liquid shots (convenience). Customer lifetime value: powder users (18 months average), liquid shot users (12 months but higher monthly spend).
- Medical / Therapeutic Users (pain management, anxiety, opioid withdrawal): Often prefer capsules or tinctures (consistent dosing, discrete). Medical users are more price-sensitive (chronic use) and more concerned with product testing (contaminants, heavy metals). This segment drives demand for mitragynine potency standardization and third-party certification.
- Recreational / Mood-Enhancement Users: Prefer liquid shots (fast onset, potent) or gummies (fun, social). Less price-sensitive, more brand-loyal. This segment is driving premiumization (USD 25+ shots).
4. Key Market Players and Strategic Positioning (2026 Update)
The kratom extract market is moderately concentrated, with top 5 players holding 52% share:
- MIT45 (USA): Holds an estimated 15% share. Market leader in liquid shots (22% of liquid segment). Differentiators: highest potency (200mg mitragynine in “Gold” shot), extensive retail distribution (smoke shops, gas stations, convenience stores), and strong brand recognition. Expanding into capsules and gummies. Growing at 20% CAGR.
- VivaZen (USA): Holds 12% share. Strong in liquid shots (second place) and tinctures. Differentiators: wellness positioning (“Zen” branding, relaxation focus), subscription model (online), and cGMP certification. Growing at 15% CAGR.
- Happy Hippo (USA): Holds 10% share. Strong across all formats (powder, capsules, liquids, gummies). Differentiators: strong brand personality, extensive educational content (blog, strain guides), loyalty program, and AKA GMP-certified. Growing at 12% CAGR.
- Koi CBD (USA): Holds 8% share. CBD company that expanded into kratom (leverages existing distribution and brand trust). Differentiators: cross-marketing with CBD products (synergy for anxiety/pain customers), professional packaging, and retail presence in CBD stores. Koi’s kratom products are priced at premium (20-30% above market average). Growing at 18% CAGR.
- Kats Botanicals (USA): Holds 7% share. Differentiators: “farmer-direct” sourcing (Indonesian plantations), sustainability claims, and strong powder selection (40+ strains). Lower exposure to liquid segment (15% of revenue). Growing at 8% CAGR.
- Others (Kratomade, DBZ Enterprises, Kraken Kratom, Super Speciosa, Kr8om, Club13 Herbals, and 100+ smaller brands): Collectively hold 48% share. Highly fragmented; many regional or online-only brands.
Industry consolidation trend: Top 5 share increased from 42% (2022) to 52% (2025) as smaller brands exited due to regulatory costs and payment processing challenges.
5. Technical Hurdles and Regulatory Landscape (2025–2026 Updates)
Despite market growth, four persistent challenges remain:
- Alkaloid Standardization and Quality Control: Mitragynine potency standardization is voluntary (no FDA mandate). Products vary widely (30-250mg per serving). Contaminants (salmonella, E. coli, heavy metals like lead, nickel) have been found in 15-20% of tested products (consumer-initiated lab studies, 2025). American Kratom Association (AKA) GMP certification covers ~35% of market (including top brands). Kratom alkaloid profile transparency (full alkaloid panel, not just mitragynine) is even rarer.
- Regulatory Patchwork (2026 Update): US federal: Not controlled, but FDA has issued import alerts and warning letters. State level: Banned in AL, AR, IN, RI, VT, WI. Regulated (Kratom Consumer Protection Acts) in UT, GA, AZ, NV, CO, FL (pending). Several other states have legislation in process. Powder-to-liquid substitution is partly driven by regulatory differences (some states ban powder but allow liquid; others vice versa).
- Credit Card Processing and Banking Access: Kratom is designated “high-risk” by payment processors (Mastercard, Visa). Higher fees (5-8% vs. 2-3% normal), frequent account freezes, and processor terminations. Some brands have moved to cryptocurrency or ACH transfers. This barrier disproportionately affects smaller brands, accelerating consolidation.
- Health Research Gaps: Limited clinical studies on long-term safety, efficacy for specific conditions (pain, anxiety, opioid use disorder), and drug interactions. FDA cites lack of research as justification for regulatory caution. Industry-funded research (e.g., Johns Hopkins University kratom studies) is ongoing but insufficient for FDA acceptance as dietary supplement.
6. Exclusive Market Forecast Summary (2026–2032)
Based on cross-referenced regression modeling (regulatory scenarios, format preference trends, and consumer adoption), this report concludes:
- Most optimistic scenario (federal clarity with regulation): Total market reaches USD 750 million by 2032 (CAGR 13.0%), driven by US federal KCPA passage (nationwide regulation, not ban), FDA acceptance of kratom as dietary supplement with GMP requirements, and European re-legalization trends. Liquid segment reaches 45% share; gummies reach 18% share. Top 5 brands reach 65% share.
- Baseline scenario (most likely – continued patchwork regulation): Total market reaches USD 540 million by 2032 (CAGR 7.9%). Liquid segment maintains 32-35% share, growing fastest (9-10% CAGR). Powder declines to 25-26% share. Online channel grows to 40-42% share (up from 36% in 2025). Average mitragynine price per gram declines (efficiency, competition). Top 5 brands reach 55-58% share.
- Downside scenario (federal ban or widespread state bans): If DEA schedules kratom as Schedule I or 10+ additional states ban, market could contract to USD 220 million by 2032 (CAGR -3.0%). Online sales would be severely restricted, and only a few large brands would survive via diversification (other botanicals) or international sales.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
